Protein kinases, which serve critical functions in signaling pathways in all cells, are popular therapeutic targets. At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency. Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compounds target more than one kinase. Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities. In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.
artificial, transforming kinase expressed in all patients with CML, it represents an ideal therapeutic target for a selective PTK inhibitor. In fact, a highly successful inhibitor, imatinib, was generated and revolutionized the treatment of CML 9 . This drug established that targeting PTKs is safe and is even tolerated better than conventional antineoplastic therapies 10, 11 .
Some solid tumors show high expression of RTKs including EGFR (encoded by ERBB1) and HER-2 (also called Neu, encoded by ERBB2). The EGFR inhibitors gefitinib and erlotinib were first approved for non-small-cell lung cancer. Patients with pancreatic tumors also benefit from erlotinib, and the effectiveness of EGFR antagonism in colorectal cancer, malignant glioma, squamous cell cancer of head and neck, breast cancer and other tumors is under evaluation. The PTK inhibitor lapatinib is used in patients with advanced breast cancer that expresses HER-2 (ref. 12 ).
Lack of specificity: maybe not so bad after all
Whereas imatinib was designed to selectively inhibit BCR-Abl, we now know that this drug has activity against several kinases, including the RTKs PDGFR and KIT, as well as colony stimulating factor 1 receptor (CSF1R) and LCK (ref. 13) (Fig. 1) . This lack of selectivity was fortuitous in that, analogously to the fusion protein causing CML, the fusion proteins FIP1L1-PDGFRA and COL1A1-PDGF-B cause hypereosinophilic syndrome and dermatofibrosarcoma protuberans, respectively 14, 15 . Similarly, systemic mastocytosis is associated with mutations of KIT, and gastrointestinal stromal tumors overexpress KIT. Imatinib treatment shows therapeutic benefit for these disorders. PDGF is also thought to be involved in the pathogenesis of systemic sclerosis; consequently, imatinib is also being tested in clinical trials for this disorder 16 . Very recently, imatinib was reported to improve type I autoimmune diabetes in mice, apparently by inhibiting PDGFR 17 . At present, more than 100 clinical trials are underway gauging the effectiveness of imatinib in disorders including non-Hodgkin's lymphoma; ovarian, prostate, breast and lung cancer; glioblastoma multiforme; malignant mesothelioma; melanoma; and chronic graft-versus-host disease.
Even though imatinib is effective in most patients with CML, leukemic cells can become resistant to imatinib as a result of mutations that render BCR-Abl less sensitive to imatinib 18 . In other tumors, mutation of 'gatekeeper' residues in EGFR, KIT or PDGFRA result in stabilization of active kinase conformations and reduced access to ATP-competitive PTK inhibitors 19 . These observations sparked development of other PTK inhibitors for drug-resistant patients. Second-generation BCR-Abl inhibitors such as dasatinib also inhibit PDGFR, KIT and CSF1R, as well as Src-family PTKs, Tec and p38α. Sorafenib and sunitinib, which are approved for the treatment of renal cell cancer, bind with nanomolar potency more than 15 and 50 kinases, respectively 13 (Fig. 1) . Consequently, several studies are testing the efficacy of sorafenib in a wide range of tumors. Despite the broad actions of sorafenib, its toxicity is acceptable-at least in the setting of treatment for malignancy. Similarly sunitinib, like imatinib, was reported to be useful in a model of type I diabetes 17 . Several phase 1 and 2 clinical trials are even investigating the safety and efficacy of 7-hydroxystaurosporine (UCN-01), an analog of staurosporine, which binds to more than 250 kinases, in patients with advanced, metastatic or refractory cancers such as pancreatic cancer, kidney cancer, melanoma and lymphoma.
It seems contrary to expectations that, in contrast to traditional chemotherapeutic agents, whose efficacy is limited by toxicity, an inhibitor with such a broad spectrum of targets would not have overwhelming toxicity. However, the threshold of acceptable toxicity is higher in drug trials involving oncology patients than in trials involving patients with chronic inflammatory disease. Although the US Food and Drug Administration (FDA)-approved kinase inhibitors mentioned here have acceptable toxicity profiles, several candidate compounds failed early drug trials. Compounds that have been especially disappointing are the p38 MAPK inhibitors. p38 MAPK was discovered through the use of kinase inhibitors, and initial work suggested that this kinase would be an ideal target in the treatment of inflammatory disease 20 . However, despite the best attempts of the pharmaceutical industry and the existence of several candidate compounds, attempts at bringing a p38 MAPK inhibitor to market failed because of drug toxicity.
Targeting Jaks
Cytokines are crucial for development, survival, proliferation and differentiation of hematopoietic cells. Type I and type II cytokine receptors lack receptor-intrinsic tyrosine kinase activity and instead transmit their signals through receptor-associated Janus kinases (Jak1, Jak2, Jak3 and Tyk2). In principle, all four Jaks might be considered useful targets; however, germline targeting of Jak1 and Jak2 results in perinatal and embryonic lethality, respectively. The hormone-like cytokines growth hormone, prolactin, erythropoietin and thrombopoietin, as well as granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5, signal through Jak2. IL-6, IL-10, IL-11,
Sorafenib Figure 1 The kinome binding maps of seven of the eight FDA-approved kinase inhibitors (sunitinib, sorafenib, imatinib, dasatinib, erlotinib, gefitinib and lapatinib), compared to the pan-inhibitor staurosporine (which affects more than 250 kinases) and to the investigational protein kinase inhibitors CP-690550 and VX-680. Even though none of the approved protein kinase inhibitors is absolutely selective, toxicity is limited. The diameter of the red circle is indirectly correlated with the affinity with which the inhibitor binds to the kinase; the cluster at the upper left of the dendrogram represents the tyrosine kinases. (Modified from Karaman et al. 13 .)
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IL-19, IL-20, IL-22 and interferon (IFN)-γ signal through Jak1 and Jak2 (Fig. 2) . In contrast, humans and mice lacking Jak3 show a distinct primary immunodeficiency disorder designated T -B + NK -severe combined immunodeficiency (SCID) 21, 22 . Jak3 is the only Jak family member that associates with just one cytokine receptor subunit-the common γ-chain (γ c ), which is exclusively used by the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 (Fig. 2) . These cytokines are critically involved in T and natural killer (NK) cell development and B cell function. By contrast, γ c -dependent cytokines are not important for the development or function of organs or tissues outside the immune system. Thus, a Jak3-specific inhibitor should have limited but precise effects on immune system cells and should leave other cell types unaffected. Given its highly specific functions, one might predict that a Jak3 antagonist might be superior to the calcineurin inhibitors cyclosporine and tacrolimus. These drugs are selective and target an important signaling pathway; however, this pathway is operative in cells both within and outside of the immune system. These drugs are thus hampered by nonimmunological side effects. In particular, calcineurin inhibitors are nephrotoxic, a considerable problem in the setting of renal transplantation. Similarly, corticosteroids are highly effective immunosuppressants, but they have many side effects, including diabetes, hypertension and osteoporosis. In principle, many of these adverse events could be avoided by therapeutics that selectively target PTKs involved exclusively in immune cell signaling. Biologics such as tumor necrosis factor antagonists are highly selective and effective in rheumatoid arthritis and inflammatory bowel disease. They are reasonably well tolerated in most patients, but their use is associated with increased incidence of serious infections and can exacerbate some autoimmune diseases. Furthermore, not all patients respond, and the drugs are very costly. An oral drug might be cheaper and more convenient. Thus, Jak3 is conceivably an ideal target, and an efficient and safe selective Jak3 inhibitor could, in theory, revolutionize the therapy of autoimmune diseases and transplant rejection, as imatinib did for CML.
Tyk2 has broader functions than Jak3, as it binds to several cytokine receptor subunits (Fig. 2) . Tyk2-deficient mice are viable but have reduced sensitivity to IFNs, IL-12 and IL-23 (ref. 23) , and show increased susceptibility to some microbial pathogens. As yet, only one human patient with a Tyk2 deficiency has been described; cells from this individual showed impaired signaling in response to type I IFNs, IL-12, IL-23, IL-10 and IL-6. This patient had a primary immunodeficiency disorder characterized as a hyper-IgE-like syndrome with many opportunistic infections by viruses, bacteria and fungi 24 . In addition, we now know that IL23R variants are strongly associated with the susceptibility to Crohn's disease, ankylosing spondylitis and psoriasis 25, 26 . Accordingly, ustekinumab, which targets the p40 subunit of IL-23 and IL-12, seems to have efficacy in these diseases 27 . Thus, a Tyk2 inhibitor could conceivably be very effective in treating diseases influenced by IL-23.
Experience with Jak3 inhibitors
The appeal of inhibiting Jak3 was widely appreciated, but one compound, CP-690550, has been most intensively studied in mouse and man. Initial studies showed that this drug was highly efficacious in transplant rejection in animal models 28 . Subsequent studies in arthritis and asthma models showed that CP-690550 was effective in these inflammatory diseases. Use of the drug was associated with a reduction in NK cell numbers and IFN-γ and IL-6 production, but it did not result in significant reduction in T or B cells. In preclinical models, the drug was also noted to cause anemia.
On the basis of the efficacy in animals, phase 1 and 2 clinical trials with CP-690550 have commenced in rheumatoid arthritis, psoriasis, Crohn's disease and renal transplant rejection, and preliminary data show efficacy with limited toxicity. In a phase2 study in rheumatoid arthritis involving hundreds of subjects, approximately two-thirds had some response (20% improvement in the American College of Rheumatology (ACR) criteria) and one-quarter of patients had a strong response (70% ACR improvement) 29 . Of note, this response was achieved in cases that failed to respond to previous therapies including methotrexate and tumor necrosis factor antagonists. In addition, it seems that CP-690550 can be used in combination with standard rheumatoid arthritis therapies such as methotrexate and glucocorticosteroids 30 . Efficacy was also observed in psoriasis, and no graft loss was reported in the setting of kidney transplantation 31, 32 . Consistent with preclinical data, Jak3 inhibition resulted in a decrease in NK cell numbers with no reduction in CD4 + or CD8 + T cell numbers 32 . However, use of CP-690550 seems to be associated with increased incidence of infections, especially in combination with other immunosuppressive drugs. Anemia has also been observed in humans treated with CP-690550, as have increases in serum lipids.
The reduction in NK cells is presumably related to antagonism of IL-15, a cytokine that is important for NK cell homeostasis. Increased incidence of infection is an expected effect of any potent immunosuppressive drug. But what about anemia? Jak2 signaling is essential for the actions of erythropoietin, and the most likely explanation for the anemia Figure 2 Targeting cytokine signaling pathways using Jak inhibitors. Jak3 has been viewed as an ideal target, as a truly specific Jak3 inhibitor would inhibit only γ c -chain-containing cytokine receptors.
However, whether such a high degree of selectivity is essential, or even beneficial, remains to be determined. Compounds selectively directed against Jak1, Jak2 or Tyk2 would affect a broader range of cytokine receptors.
P E r s P E C T i V E
seen in these trials is the inhibitory effects of CP-690550 on Jak2 (ref. 33) . Although the drug was initially thought to be selective for Jak3, a recent study has called this conclusion into question 13 . Compared to most other PTK inhibitors, CP-690550 affects a very restricted number of targets within the human kinome. However, the data indicate that CP-690550 binds Jak3 and Jak2 with roughly equivalent affinity (2.2 nM and 5 nM, respectively) 13 . This study did not include Jak1 in the screen, but it raises the possibility that some of the efficacy of CP-690550 might be due to inhibition of Jak1 or Jak2 as well Jak3. CP-690550 is apparently not a potent inhibitor of Tyk2.
Jak2 and polycythemia vera
The lethality associated with germline deletion of Jak2 was certainly grounds for caution in developing compounds that might interfere with Jak2. However, the discovery of a subset of diseases associated with Jak2 mutations provided reason to consider the therapeutic use of Jak2 inhibitors. Polycythemia vera and essential thrombocytosis are MPDs that typically run an indolent course, with a proportion developing into myelofibrosis or acute myeloblastic leukemia. More than 95% of cases of polycythemia vera and 50% of cases of essential thrombocytosis and myelofibrosis are associated with point mutations in Jak2 (refs. [34] [35] [36] [37] . The most common mutation, V617F, is located within the JH2 pseudokinase domain and results in a constitutively active kinase that facilitates cytokine-independent growth of hematopoietic cells 38, 39 . At present, there are at least fifteen clinical trials in MPD using various PTK inhibitors that target Jak2. Several reportedly selective Jak2 inhibitors are being studied. Lestaurtinib, dasatinib and the aurora kinase inhibitor MK-0457 (VX-680) have also been reported to have activity against mutated Jak2 and are under evaluation for polycythemia vera. Even imatinib, which apparently has little in vitro activity toward Jak2, is being tested in polycythemia vera. In contrast to the data obtained from in vitro screens, a recent report indicated that CP-690550 has relatively little activity against unmutated Jak2 but shows stronger activity in cells with mutated Jak2 (ref. 40) . Another compound, INCB018424, has been reported to be a potent Jak2 and Jak1 antagonist and is being tested in MPD, but it is also being studied in other cancers in which Jak2 mutations have not been identified, including prostate cancer, multiple myeloma, acute myelogenous leukemia and CML. From all these trials, we will learn much about whether it is safe to inhibit Jak2 in humans.
Selective inhibition of Jaks: good or bad?
Whereas avoiding activity against Jak1 and Jak2 would have been considered essential in the early days of designing Jak inhibitors, inhibition of Jak1 and Jak2 is no longer viewed as an obstacle and might even be considered beneficial. INCB018424 reportedly had efficacy in preclinical models of arthritis and is now being studied in phase 2 studies for rheumatoid arthritis. In preliminary results, ten patients (83%) treated with INCB018424 had some response (a 20% improvement in ACR criteria) 41 . The efficacy of such a drug is perhaps not surprising, as a Jak1 and Jak2 inhibitor would target γ c -, gp130-and common-β-chain-containing cytokine receptors (GM-CSF receptor, IL-3R, IL-5R), as well as receptors for IL-12 and IL-23, IFNs and other type II cytokines, colony stimulating factors and hormone-like cytokines. This drug reportedly has little activity against Jak3, but functionally, this should make little difference as all receptors that use Jak3 also use Jak1 for signaling. Curiously, though, no cytopenias were reported in this small study. The comparative efficacy and toxicity of the various Jak inhibitors will be important to follow in longer-term studies. Another compound, R348, has also entered phase 1 trials for rheumatoid arthritis and psoriasis. R348 is a Jak3 inhibitor, but it also inhibits Syk, which is structurally related to ZAP-70 and has two SH2 domains. Through these SH2 domains, Syk binds to immunoreceptors including Fc and NK receptors, integrin receptors, and Dectin-1. Syk inhibitors such as R788 are also under clinical investigation in phase 2 trials for rheumatoid arthritis. Preliminary results show efficacy but also dose-dependent neutropenia 42 . Conceivably, there may be considerable benefit in inhibiting members of two classes of immunologically relevant kinases; however, the relative toxicity of a more selective Jak inhibitor versus a Jak and Syk inhibitor will need to be ascertained. At this point, the jury is still out.
The future of kinase inhibition for immunological disease Eight PTK inhibitors have now been approved by the FDA. Initially, it seemed essential to generate highly selective compounds to achieve efficacy without profound toxicity. However, drugs with remarkably little selectivity are being routinely used in the treatment of cancer, and the lack of selectivity is now considered an attribute. Moreover, in certain oncological settings, the combination of kinase inhibitors with different targets may be more beneficial to achieve better response rates and to overcome resistance attributable to the activation of multiple oncogenic signaling pathways. Two approaches are conceivable-the simultaneous use of more than one kinase inhibitor or the intentional generation of inhibitors targeting more than one kinase with nanomolar potency; the latter would represent a first step toward targeted polypharmacology 43, 44 . Although it made a great deal of sense to try to develop specific inhibitors, the complexity of biological systems might make it advantageous to target multiple kinases. Maybe a degree of nonselectivity is more tolerable than we originally thought, and there may be circumstances wherein this might provide better efficacy.
At present, we cannot 'cure' autoimmune diseases, and as a result, these diseases require lifelong treatment with immunosuppressants. It is worth recalling that drugs used to treat autoimmune disease, such as methotrexate and cyclophosphamide, were initially used in the setting of malignancy, albeit at higher doses than those commonly used in rheumatology patients. To what extent we will be able to use 'broad spectrum' kinase inhibitors in patients with immunity-mediated disease remains to be determined. It is tempting to speculate that we may soon see the use of drugs like dasatinib and sunitinib for the treatment of human autoimmune disease. Regardless, we are witnessing a sea change with respect to the need for selectivity, and it will be fascinating to see where the pendulum comes to rest.
